LAMEA Cartilage Repair Market By Modality (Cell Based - Chondrocyte Transplantation, Growth Factor; Non-Cell-Based - Tissue Scaffolds Systems, Cell-Free Composites, Application (Hyaline Cartilage, Fibrocartilage), Treatment Type (Palliative - Viscosupplementation, Debridement & Lavage; Intrinsic Repair Stimulus), Site Outlook (Knee - Arthroscopic Chondroplasty, Autologous Chondrocyte, Osteochondral Grafts, Cell-based Cartilage Resurfacing, Microfracture)
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the LAMEA Cartilage Repair Market
Market Report Description
The Latin America, Middle East and Africa Cartilage Repair Market would witness market growth of 10.2% CAGR during the forecast period (2018 - 2024).
If cartilage damage remains untreated, it would lead to knee replacement surgery. The tissue prevents friction between the bones, by absorbing shock in the joints. When damage is caused in the cartilage, it restricts the regular movement of the knee, causing immense pain. It generally occurs after a traumatic and twisting injury to the knee. Emerging markets are highly potential market; therefore, vendors are majorly focusing on Asia- LAMEA for expansion activities. Also, LAMEA would be a region with tremendous market potential due to increasing investment into R&D and surge in osteoarthritis awareness.
Based on Modality, the market is segmented into Cell based and Non-Cell based. Based on Treatment type, the market is segmented into Intrinsic Repair Stimulus and Palliative. Based on Application, the market is segmented into Fibrocartilage and Hyaline Cartilage. Based on Site outlook, the market is segmented into Knee Cartilage and Other site outlook. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include B. Braun Melsungen AG, Zimmer Biomet, Johnson and Johnson, Smith & Nephew Plc., Stryker Corporation, Vericel Corporation, Osiris Therapeutics Inc., Arthrex, Inc., Collagen Solutions Plc., and Anika Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Modality
- Cell-Based:
- Chondrocyte Transplantation
- Growth Factor Technology
- Non-Cell-Based
- Tissue Scaffolds
- Cell-Free Composites
By Treatment type
- Intrinsic Repair Stimulus
- Palliative
- Debridement & Lavage
- Viscosupplementation
By Application
- Fibrocartilage
- Hyaline Cartilage
By Site outlook
- Knee Cartilage Repair
- Microfracture
- Arthroscopic Chondroplasty
- Autologous Chondrocyte
- Osteochondral Grafts Transplantation
- Cell-based Cartilage Resurfacing
- Others
- Other Site Outlook
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- B. Braun Melsungen AG
- Zimmer Biomet
- Johnson and Johnson
- Smith & Nephew Plc.
- Stryker Corporation
- Vericel Corporation
- Osiris Therapeutics Inc.
- Arthrex, Inc.
- Collagen Solutions Plc.
- Anika Therapeutics, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free